Major facilitator superfamily transporter that mediates resistance to structurally and functionally unrelated compounds including cycloheximide but also azoles such as fuconazole, ketoconazole and itraconazole (PubMed:11065353, PubMed:11181345). Mediates also efflux of histatin 5, a salivary human antimicrobial peptide, and is responsible for reduction of its toxicity in C.albicans (PubMed:23380720, PubMed:28953977). Expression is positively regulated by the CAP1 transcription activator (PubMed:19395663). Expression is also regulated by the MRR1 transcription factor (PubMed:28953977). Expression is inhibited by tetrandrine (TET), a compound known to act in a synergistic manner with fluconazole (PubMed:19420894, PubMed:23527892). Expression is increased in clinical azole-resistant isolates (PubMed:23769565, PubMed:24962255). Increases the susceptibility to mycophenolic acid, fuconazole, ketoconazole and itraconazole (PubMed:11065353). Reduces the efflux of spermidine as well as of histatin 5, a salivary human antimicrobial peptide that is toxic to the opportunistic yeast C.albicans (PubMed:23380720). Leads also to reduced biofilm formation (PubMed:23380720). Belongs to the major facilitator superfamily. DHA1 family. Polyamines/proton antiporter (TC 2.A.1.2.16) subfamily.